Veru Valuation
Is FMW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of FMW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: FMW (€0.6) is trading below our estimate of fair value (€13.73)
Significantly Below Fair Value: FMW is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FMW?
Key metric: As FMW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is FMW's PS Ratio? | |
|---|---|
| PS Ratio | 7x |
| Sales | US$14.09m |
| Market Cap | US$91.91m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.4x |
| Enterprise Value/EBITDA | -1.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does FMW's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 74x | ||
SHOT Safety Shot | 278.3x | n/a | US$52.8m |
A239610 HLscience | 3x | n/a | ₩66.0b |
PAVS Paranovus Entertainment Technology | 9.9x | n/a | US$62.6m |
A123330 Genic | 4.8x | n/a | ₩138.5b |
FMW Veru | 7x | 40.8% | €91.9m |
Price-To-Sales vs Peers: FMW is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (74x).
Price to Sales Ratio vs Industry
How does FMW's PS Ratio compare vs other companies in the European Personal Products Industry?
| 7 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: FMW is expensive based on its Price-To-Sales Ratio (7x) compared to the European Personal Products industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is FMW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 7x |
| Fair PS Ratio | 5.7x |
Price-To-Sales vs Fair Ratio: FMW is expensive based on its Price-To-Sales Ratio (7x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.60 | €3.11 +418.7% | 44.0% | €4.58 | €0.92 | n/a | 5 |
| Nov ’25 | €0.68 | €3.11 +359.6% | 44.0% | €4.58 | €0.92 | n/a | 5 |
| Oct ’25 | €0.68 | €3.11 +358.3% | 44.0% | €4.58 | €0.92 | n/a | 5 |
| Sep ’25 | €0.73 | €3.11 +327.8% | 44.0% | €4.58 | €0.92 | n/a | 5 |
| Aug ’25 | €0.86 | €3.12 +262.9% | 44.0% | €4.59 | €0.92 | n/a | 5 |
| Jul ’25 | €0.78 | €3.20 +312.8% | 41.7% | €4.66 | €1.12 | n/a | 5 |
| Jun ’25 | €0.88 | €3.18 +262.7% | 41.7% | €4.62 | €1.11 | n/a | 5 |
| May ’25 | €1.15 | €3.14 +172.5% | 37.4% | €4.71 | €1.88 | n/a | 3 |
| Apr ’25 | €0.68 | €3.69 +439.5% | 54.0% | €6.47 | €1.85 | n/a | 3 |
| Mar ’25 | €0.55 | €4.07 +635.5% | 55.6% | €6.32 | €1.81 | n/a | 2 |
| Feb ’25 | €0.45 | €4.07 +812.0% | 55.6% | €6.32 | €1.81 | n/a | 2 |
| Jan ’25 | €0.68 | €4.07 +501.5% | 55.6% | €6.32 | €1.81 | n/a | 2 |
| Dec ’24 | €0.86 | €3.06 +254.7% | 78.7% | €6.42 | €0.92 | n/a | 3 |
| Nov ’24 | €0.85 | €3.06 +258.9% | 78.7% | €6.42 | €0.92 | €0.68 | 3 |
| Oct ’24 | €0.70 | €3.06 +335.2% | 78.7% | €6.42 | €0.92 | €0.68 | 3 |
| Sep ’24 | €0.95 | €3.06 +223.1% | 78.7% | €6.42 | €0.92 | €0.73 | 3 |
| Aug ’24 | €1.13 | €3.65 +223.1% | 89.0% | €8.21 | €0.91 | €0.86 | 3 |
| Jul ’24 | €1.07 | €3.94 +267.7% | 73.2% | €8.35 | €0.93 | €0.78 | 4 |
| Jun ’24 | €0.94 | €3.91 +316.3% | 73.2% | €8.27 | €0.92 | €0.88 | 4 |
| May ’24 | €1.14 | €7.33 +545.8% | 59.3% | €13.75 | €1.83 | €1.15 | 4 |
| Apr ’24 | €1.11 | €9.46 +749.4% | 51.5% | €14.18 | €1.89 | €0.68 | 4 |
| Mar ’24 | €3.68 | €10.47 +184.9% | 47.6% | €13.97 | €1.86 | €0.55 | 4 |
| Feb ’24 | €5.28 | €17.42 +230.1% | 48.2% | €28.72 | €2.78 | €0.45 | 5 |
| Jan ’24 | €4.91 | €17.89 +264.1% | 48.2% | €29.49 | €2.85 | €0.68 | 5 |
| Dec ’23 | €5.32 | €25.12 +371.8% | 35.9% | €35.32 | €9.81 | €0.86 | 5 |
| Nov ’23 | €12.33 | €34.13 +176.9% | 30.1% | €53.33 | €23.27 | €0.85 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
L'Oréal
€176.0b
Through its subsidiaries, manufactures and sells cosmetic products for women and men worldwide.
LOR
€329.75
7D
1.4%
1Y
-23.3%
Cheerwin Group
HK$2.5b
An investment holding company, manufactures and trades household insecticides and repellents, household cleaning, air care, personal care, pets and pet products, and other products in the People’s Republic of China.
1RQ
HK$0.21
7D
-2.8%
1Y
26.5%
McBride
UK£182.8m
Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.
10W
UK£1.21
7D
6.1%
1Y
80.6%